The short version of WADA prohibited list fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-27. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Class I has two highly conserved sequence motifs. It aminoacylates at the 2'-OH of a terminal adenosine nucleotide on tRNA, and it is usually monomeric or dimeric (one or two subunits, respectively). Class II has three highly conserved sequence motifs. It aminoacylates at the 3'-OH of a terminal adenosine on tRNA, and is usually dimeric or tetrameric (two or four subunits, respectively). Although phenylalanine-tRNA synthetase is class II, it aminoacylates at the 2'-OH. The amino acids are attached to the hydroxyl (-OH) group of the adenosine via the carboxyl (-COOH) group. Regardless of where the aminoacyl is initially attached to the nucleotide, the 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification. Bacterial aminoacyl-tRNA synthetases can be grouped as follows:
With security largely under the purview of the BPC, corporate control of the park has meant that Bryant Park received passive-recreation amenities, while excluding active sports that might cater to a broader urban public. The BPC added a custom-built carousel in 2002 and revived the tradition of an open-air library, the Reading Room, in 2003. In July 2002, the park launched a public wireless network, making the park the first in New York City to formally offer free Wi-Fi access to visitors. The Wi-Fi system was subsequently upgraded in 2008. Furthermore, the Pond, a free-admission ice skating rink, opened in the park in 2005. The park's public restrooms were renovated in 2006 and in 2017. The dramatic rise in real estate values in the area around Bryant Park, as well as new construction in adjacent areas, was a consequence of the park's improvements. By 1993, the surrounding region had become a highly desirable office area, and formerly vacant office space around the park was being filled quickly. By the first decade of the 21st century, nearby buildings and businesses were also using names that referred to the park. This was shown by the then-new Bank of America Tower skyscraper at the park's northeast corner using the address "One Bryant Park", as well as the growing trend of Bryant Park vanity addresses, including 3, 4, 5, and 7 Bryant Park. National Public Radio, located just south of the park, also named a now-defunct talk show the "Bryant Park Project" upon the show's 2007 launch.
=== Awards and distinctions === As of 2022, Palmer has four active RO1's from the National Institutes of Health for bioengineering research projects. He has multiple collaborations from research labs across the U.S. In 2021, Palmer received the Gaden Award from the Biotechnology & Bioengineering (journal) in recognition for a truly outstanding paper. In 2015, Palmer was inducted fellow of the American Institute for Medical and Biological Engineering "for pioneering advances in engineering novel hemoglobin-based oxygen carriers for use as red blood cell substitutes in transfusion medicine." In 2008, Palmer received the Lloyd Noel Ferguson Young Scientist award from the National Organization for the Professional Advancement of Chemists and Chemical Engineers (NOBCHE). In 2001, Palmer was a recipient of the National Science Foundation CAREER Award for "engineering artificial cells.”
== Side effects and withdrawal from market == On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx. Other reported side effects were angina and Stevens–Johnson syndrome. Pfizer first acknowledged cardiovascular risks associated with Bextra in October 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos. In a large study published in The Journal of the American Medical Association in 2006, valdecoxib appeared less adverse for renal (kidney) disease and heart arrhythmia compared to Vioxx, but elevated renal risks were slightly suggested.
Sources: en.wikipedia.org
The September 11 terrorist attacks were a major turning point in Bush's presidency. That evening, he addressed the nation from the Oval Office, promising a strong response to the attacks. He also emphasized the need for the nation to come together and comfort the families of the victims. Three days after the attacks, Bush visited Ground Zero and met with then-New York City Mayor Rudy Giuliani, firefighters, police officers, and volunteers. Bush addressed the gathering via a megaphone while standing on rubble: "I can hear you. The rest of the world hears you. And the people who knocked these buildings down will hear all of us soon." In a September 20 speech, Bush condemned Osama bin Laden and his organization al-Qaeda, and issued an ultimatum to the Taliban regime in Afghanistan, where bin Laden was operating, to "hand over the terrorists, or ... share in their fate". The Taliban's leader, Mullah Omar, refused to hand over bin Laden. The continued presence of U.S. troops in Saudi Arabia after the 1991 Gulf War was one of the stated motivations behind the September 11 attacks. In 2003, the U.S. withdrew most of its troops from Saudi Arabia.
=== Helix structure === In 1948, Pauling discovered that many proteins included helical (see alpha helix) shapes. Pauling had deduced this structure from X-ray patterns and from attempts to physically model the structures. (Pauling was also later to suggest an incorrect three chain helical DNA structure based on Astbury's data.) Even in the initial diffraction data from DNA by Maurice Wilkins, it was evident that the structure involved helices. But this insight was only a beginning. There remained the questions of how many strands came together, whether this number was the same for every helix, whether the bases pointed toward the helical axis or away, and ultimately what were the explicit angles and coordinates of all the bonds and atoms. Such questions motivated the modeling efforts of Watson and Crick.
== Physical properties == The melting point of cerebrosides is considerably greater than physiological body temperature, >37.0 °C, giving glycolipids a paracrystalline, similar to liquid crystal structure. Cerebroside molecules are able form up to eight intermolecular hydrogen bonds between the polar hydrogens of the sugar and the hydroxy and amide groups of the sphingosine base of the ceramide. These hydrogen bonds within the cerebrosides result in the molecules having a high transition temperature and compact alignment. Monoglycosylceramides in conjunction with cholesterol are prevalent in the lipid-raft micro domain, which are important sites in the binding of proteins, and enzyme-receptor interactions.
=== Angiotensin III === Amino acid sequence: Asp | Arg-Val-Tyr-Ile-His-Pro-Phe Angiotensin III, along with angiotensin II, is considered an active peptide derived from angiotensinogen. It is formed by removing an amino acid from angiotensin II by glutamyl aminopeptidase A, which cleaves the N-terminal Asp residue. Angiotensin III has 40% of the pressor activity of angiotensin II, but 100% of the aldosterone-producing activity. It increases mean arterial pressure. Activation of the AT2 receptor by angiotensin III triggers natriuresis, while AT2 activation via angiotensin II does not. This natriuretic response via angiotensin III occurs when the AT1 receptor is blocked.
On 8 September 2026, artificial intelligence company OpenAI announced it had solved the Millennium Prize Problem on the existence and smoothness of the incompressible Navier–Stokes equations in three-dimensional Euclidean space. OpenAI stated that the solution to the problem, a counterexample that refers to statements C and D of the problem statement, was developed by its researchers using as many as 10,000 coordinated agents running an internal frontier model, along with a formalization in the Lean proof assistant. The claim has not been verified by external mathematicians or the Clay Mathematics Institute, while OpenAI stated it would not claim the Millennium Prize. The announcement was accompanied by a priority dispute with Levent Alpöge (employed at rival AI company Anthropic) and Tristan Buckmaster, who had derived a set of closely related results on the Euler equations. The method used to generate the claimed solution built upon a method developed by Diego Córdoba and Luis Martínez Zoroa in 2023 to prove blowup phenomena in related fluid equations.
Sources: en.wikipedia.org
This process is extremely painful and can traumatize the animal. Freeze branding gained popularity in the middle of the 20th century as a less painful way to permanently mark and identify animals. There has been debate as to whether freeze branding is truly less painful than hot branding, but scientific studies conducted to compare the relative pain of the two methods have concluded that freeze branding is indeed less distressing to the animal being marked. Freeze brands are made for a variety of purposes. For example, they are used to indicate that an animal belongs to a particular herd, all members of which are marked with the same brand. They are also used to indicate via a unique pattern that an individual animal is a particular person's or ranch's property. Freeze branding is also used to tag wild animals that will be recaptured for later research.
== Publications == Active Biological Evolution: Feedback-Driven, Actively Accelerated Organismal and Cancer Evolution , Frank H. Laukien, 2022 ISBN 979-8-9854147-0-7 Origins & Evolution: Evolution of Our Universe and Planet, and the Origins of Life and Meaning Frank H. Laukien, ISBN 979-8985414721
== External links == lipopolysaccharide-binding+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Luminol in an alkaline solution with hydrogen peroxide in the presence of iron or copper, or an auxiliary oxidant, produces 3-aminophtalate in an excited state, which exhibits chemiluminescence. The luminol reaction is
=== Agonists === Finding selective agonists for PAR1 has also been a topic of interest for researchers. A synthetic SFLLRN peptide has been found to serve as an agonist for PAR1. The SFLLRN peptide mimics the first six residues of the N-terminal tethered ligand of activated PAR1 and binds to the same binding site on the second extracellular loop. So, even in the absence of thrombin, SFLLRN binding can garner a response from cleaved or uncleaved PAR1.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.